ITM2C Monoklonaler Antikörper

ITM2C Monoklonal Antikörper für IF/ICC

Wirt / Isotyp

Maus / IgG2a

Getestete Reaktivität

human, Hund

Anwendung

IF/ICC

Konjugation

CoraLite®594 Fluorescent Dye

CloneNo.

2E8G11

Kat-Nr. : CL594-60095

Synonyme

E25, CT-BRI3, Cerebral protein 14, BRICD2C, BRI3



Geprüfte Anwendungen

Erfolgreiche Detektion in IF/ICCHepG2-Zellen, MDCK-Zellen

Empfohlene Verdünnung

AnwendungVerdünnung
Immunfluoreszenz (IF)/ICCIF/ICC : 1:50-1:500
It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
Sample-dependent, check data in validation data gallery

Produktinformation

CL594-60095 bindet in IF/ICC ITM2C und zeigt Reaktivität mit human, Hund

Getestete Reaktivität human, Hund
Wirt / Isotyp Maus / IgG2a
Klonalität Monoklonal
Typ Antikörper
Immunogen ITM2C fusion protein Ag4409
Vollständiger Name integral membrane protein 2C
Berechnetes Molekulargewicht230aa,26 kDa; 267aa,30 kDa
Beobachtetes Molekulargewicht 35 kDa
GenBank-ZugangsnummerBC025742
Gene symbol ITM2C
Gene ID (NCBI) 81618
Konjugation CoraLite®594 Fluorescent Dye
Excitation/Emission maxima wavelengths588 nm / 604 nm
Form Liquid
Reinigungsmethode Protein-A-Reinigung
Lagerungspuffer PBS with 50% glycerol, 0.05% Proclin300, 0.5% BSA
LagerungsbedingungenBei -20°C lagern. Vor Licht schützen. Nach dem Versand ein Jahr stabil. Aliquotieren ist bei -20oC Lagerung nicht notwendig. 20ul Größen enthalten 0,1% BSA.

Hintergrundinformationen

The Integral membrane protein 2C (ITM2C) is a type II integral transmembrane protein belonging to a family composed of at least two other members, ITM2A and ITM2B. ITM2C, often called transmembrane protein BRI3, is highly expressed in brain tissue. Yeast two-hybrid screen system revealed that BRI3 could interact with beta-secretase beta-amyloid protein converting enzyme (BACE)1 and the microtubule-destabilizing protein SCG10 (STMN2). It may play a role in TNF-induced cell death and neuronal differentiation. BRI3 was found to inhibit the various processing of amyloid precursor protein (APP) by blocking the access of alpha- and beta-secretases to APP, competitive inhibition of APP processing by BRI3 may provide a new approach to Alzheimer disease (AD) therapy and prevention.

Protokolle

PRODUKTSPEZIFISCHE PROTOKOLLE
IF protocol for CL594 ITM2C antibody CL594-60095Protokoll herunterladen
STANDARD-PROTOKOLLE
Klicken Sie hier, um unsere Standardprotokolle anzuzeigen